Medtronic puts $700M into a surgical robot maker

Medtronic announced on 1 September 2026 that it is investing approximately $700 million in Cornerstone Robotics, the Hong Kong company behind the Sentire surgical system, and taking rights to distribute Sentire in selected markets outside the United States where it is already approved. The release does not say whether the money buys equity, a convertible instrument, or an option to acquire.

Sentire received a CE Mark in May 2026 and holds market approval in China, the European Union and Singapore, cleared for minimally invasive general, gynaecologic, thoracic and urologic procedures. Cornerstone operates three global R&D hubs, six business centres and a 30,000-square-metre manufacturing facility in China.

Medtronic frames the two systems as complementary rather than competing — a “two-platform portfolio” in which Sentire offers a familiar configuration alongside the modular, multi-quadrant Hugo. Matt Anderson, a Medtronic senior vice-president, told The Robot Report that surgeons, health systems and markets have varying needs, “which is why we are investing across robotic platforms.”

The buyer of a surgical robot is a hospital, and the capability in question belongs to the surgeon rather than the patient. What a second platform changes is how many operating rooms can be reached.